Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manon Launay

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|September 26, 2025
The misleading accuracy of propofol PK/PD models: why hypoalbuminemia mattersManon Launay, Peggy Gandia, Aline Albi-Feldzer, et al.
Therapeutic Drug Monitoring|August 25, 2022
Ceftazidime Concentration is Correlated to the Glomerular Filtration Rate and Body Mass IndexManon Launay, Cornélie Fanton d'Andon, Patricia Correia, et al.
Therapeutic Drug Monitoring|April 28, 2021
Severe Inflammation, Acute Kidney Injury, and Drug-Drug Interaction: Triple Penalty for Prolonged Elimination of Apixaban in Patients With Coronavirus Disease 2019: A Grand RoundManon Launay, Anne-Laure Demartin, Sophie Perinel Ragey, et al.
Therapie|January 22, 2025
COVID-19 infection and risk of adverse drug reactions: Cohort studyPaul-Benoît Fargier, Marlène Damin-Pernik, Manon Launay, et al.
Antibiotics (Basel, Switzerland)|August 29, 2024
Loading Dose of Ceftazidime Needs to Be Increased in Critically Ill Patients: A Retrospective Study to Evaluate Recommended Loading Dose with Pharmacokinetic ModellingManon Launay, Edouard Ollier, Benjamin Kably, et al.
The Journal of Antimicrobial Chemotherapy|January 15, 2025
Navigating the complexities of azole antifungal therapy through pharmacokinetic concepts: a case of prolonged isavuconazole toxicityManon Launay, Florian Saunier, Sarah Baklouti, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 20, 2018
How can we best monitor 5-FU administration to maximize benefit to risk ratio?Françoise Goirand, Florian Lemaitre, Manon Launay, et al.
Clinical Cancer Drugs|April 24, 2018
UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTSManon Launay, Joseph Ciccolini, Claire Fournel, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 29, 2017
An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samplesBalthazar Toussaint, Fanny Lanternier, Christian Woloch, et al.
British Journal of Clinical Pharmacology|September 23, 2015
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancerManon Launay, Laetitia Dahan, Manon Duval, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Metabolism & Toxicology|September 26, 2025
The misleading accuracy of propofol PK/PD models: why hypoalbuminemia mattersManon Launay, Peggy Gandia, Aline Albi-Feldzer, et al.
Therapeutic Drug Monitoring|August 25, 2022
Ceftazidime Concentration is Correlated to the Glomerular Filtration Rate and Body Mass IndexManon Launay, Cornélie Fanton d'Andon, Patricia Correia, et al.
Therapeutic Drug Monitoring|April 28, 2021
Severe Inflammation, Acute Kidney Injury, and Drug-Drug Interaction: Triple Penalty for Prolonged Elimination of Apixaban in Patients With Coronavirus Disease 2019: A Grand RoundManon Launay, Anne-Laure Demartin, Sophie Perinel Ragey, et al.
Therapie|January 22, 2025
COVID-19 infection and risk of adverse drug reactions: Cohort studyPaul-Benoît Fargier, Marlène Damin-Pernik, Manon Launay, et al.
Antibiotics (Basel, Switzerland)|August 29, 2024
Loading Dose of Ceftazidime Needs to Be Increased in Critically Ill Patients: A Retrospective Study to Evaluate Recommended Loading Dose with Pharmacokinetic ModellingManon Launay, Edouard Ollier, Benjamin Kably, et al.
The Journal of Antimicrobial Chemotherapy|January 15, 2025
Navigating the complexities of azole antifungal therapy through pharmacokinetic concepts: a case of prolonged isavuconazole toxicityManon Launay, Florian Saunier, Sarah Baklouti, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 20, 2018
How can we best monitor 5-FU administration to maximize benefit to risk ratio?Françoise Goirand, Florian Lemaitre, Manon Launay, et al.
Clinical Cancer Drugs|April 24, 2018
UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTSManon Launay, Joseph Ciccolini, Claire Fournel, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 29, 2017
An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samplesBalthazar Toussaint, Fanny Lanternier, Christian Woloch, et al.
British Journal of Clinical Pharmacology|September 23, 2015
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancerManon Launay, Laetitia Dahan, Manon Duval, et al.
Pageof 5